RxDoctor Payments Data

Marissa Hogan

Family · Pocahontas, ARNPI 1639621121

Payments from drug & device makers

$1,700in general payments, 2019–2025

Across 110 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$293
  • Amgen$224
  • AbbVie$211
  • Novartis$190
  • Merck$142
  • GSK$98
  • plus $543 from 15 others

What the payments were for

  • Food & beverage$1,700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,700 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$90,580
Medicare patients
222
Services billed
1,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$29,250
JardianceEmpagliflozin74$23,461
JanuviaSitagliptin Phosphate82$22,251
ProliaDenosumab12$22,200
FarxigaDapagliflozin Propanediol68$21,840
MyrbetriqMirabegron56$13,560
EliquisApixaban34$13,072
KerendiaFinerenone20$6,047
Tresiba Flextouch U-100Insulin Degludec34$5,994
Potassium Chloride197$5,785
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,367
Pregabalin90$4,765
Mirtazapine91$2,656
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc25$1,797
Oseltamivir Phosphate29$1,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$293$29,25029 claims
Boehringer IngelheimJardiance$14$23,46174 claims
MerckJanuvia$142$22,25182 claims
AmgenProlia$224$22,20012 claims
AstraZenecaFarxiga$76$21,84068 claims
PfizerEliquis$91$13,07234 claims
BayerKerendia$82$6,04720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.

Other family in Pocahontas

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →